20.24

0.05% -0.01

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Financials Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is traded at $20.24, with a volume of 1.11M. It is down -0.05% in the last 24 hours and up +8.41% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Previous Close:

$20.25

Open:

$20.14

24h Volume:

1.11M

Relative Volume:

0.74

Market Cap:

$2.33B

Revenue:

Net Income/Loss:

$-804.34M

P/E Ratio:

-2.1509

EPS:

-9.41

Net Cash Flow:

$-531.06M

1W Performance:

-11.42%

1M Performance:

+8.41%

6M Performance:

-62.15%

1Y Performance:

-51.06%

1-Day Range:

$20.01

$21.43

1-Week Range:

$18.75

$23.37

52-Week Range:

$15.79

$55.70

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

203-404-0410

Address

215 CHURCH STREET, NEW HAVEN, CT

Employee

256

Twitter

@biohavenpharma

Next Earnings Date

2022-11-07T13:30:00.000Z

Latest SEC Filings

BHVN's Discussions on Twitter

Compare BHVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHVN Biohaven Ltd	20.24	2.33B	0	-804.34M	-531.06M	-9.41
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Sep-16-24	Initiated	Jefferies	Buy
Sep-04-24	Initiated	Bernstein	Outperform
Jul-24-24	Initiated	Morgan Stanley	Overweight
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

May 09, 2025

Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.

May 09, 2025